Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers

被引:17
作者
Yoo, Scong-Keun [1 ]
Song, Young Shin [2 ]
Park, Young Joo [3 ,4 ]
Seo, Jeong-Sun [5 ,6 ,7 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[2] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Internal Med, 101 Dachak Ro, Seoul 03080, South Korea
[4] Seoul Natl Univ, Med Res Ctr, Genom Med Inst, Seoul, South Korea
[5] Seoul Natl Univ, Bundang Hosp, Precis Med Ctr, 172 Dolma Ro, Seongnam 13605, South Korea
[6] Seoul Natl Univ, Bundang Hosp, Gong Wu Genom Med Inst, Seongnam, South Korea
[7] Macrogen Inc, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Thyroid neoplasms; Thyroid carcinoma; anaplastic; Genome; Transcriptome; High-throughput nucleotide sequencing; TERT PROMOTER MUTATIONS; PATHWAY ALTERATIONS; PD-1; BLOCKADE; MOUSE MODEL; MUTANT P53; LANDSCAPE; BRAF; CARCINOMA; REPAIR; IDENTIFICATION;
D O I
10.3803/EnM.2020.35.1.44
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anaplastic thyroid cancer (ATC) is a lethal human cancer with a 5-year survival rate of less than 10%. Recently, its genomic and transcriptomic characteristics have been extensively elucidated over 5 years owing to advance in high throughput sequencing. These efforts have extended molecular understandings into the progression mechanisms and therapeutic vulnerabilities of aggressive thyroid cancers. In this review, we provide an overview of genomic and transcriptomic alterations in ATC and poorly-differentiated thyroid cancer, which are distinguished from differentiated thyroid cancers. Clinically relevant genomic alterations and deregulated signaling pathways will be able to shed light on more effective prevention and stratified therapeutic interventions for affected patients.
引用
收藏
页码:44 / 54
页数:11
相关论文
共 82 条
  • [1] Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras
    Acin, Sergio
    Li, Zhongyou
    Mejia, Olga
    Roop, Dennis R.
    El-Naggar, Adel K.
    Caulin, Carlos
    [J]. JOURNAL OF PATHOLOGY, 2011, 225 (04) : 479 - 489
  • [2] Integrated Genomic Characterization of Papillary Thyroid Carcinoma
    Agrawal, Nishant
    Akbani, Rehan
    Aksoy, B. Arman
    Ally, Adrian
    Arachchi, Harindra
    Asa, Sylvia L.
    Auman, J. Todd
    Balasundaram, Miruna
    Balu, Saianand
    Baylin, Stephen B.
    Behera, Madhusmita
    Bernard, Brady
    Beroukhim, Rameen
    Bishop, Justin A.
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Bootwalla, Moiz S.
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brookens, Robin
    Brooks, Denise
    Bryant, Robert
    Buda, Elizabeth
    Butterfield, Yaron S. N.
    Carling, Tobias
    Carlsen, Rebecca
    Carter, Scott L.
    Carty, Sally E.
    Chan, Timothy A.
    Chen, Amy Y.
    Cherniack, Andrew D.
    Cheung, Dorothy
    Chin, Lynda
    Cho, Juok
    Chu, Andy
    Chuah, Eric
    Cibulskis, Kristian
    Ciriello, Giovanni
    Clarke, Amanda
    Clayman, Gary L.
    Cope, Leslie
    Copland, John A.
    Covington, Kyle
    Danilova, Ludmila
    Davidsen, Tanja
    Demchok, John A.
    DiCara, Daniel
    Dhalla, Noreen
    [J]. CELL, 2014, 159 (03) : 676 - 690
  • [3] Comprehensive screening for PD-L1 expression in thyroid cancer
    Ahn, Soomin
    Kim, Tae Hyuk
    Kim, Sun Wook
    Ki, Chang Seok
    Jang, Hye Won
    Kim, Jee Soo
    Kim, Jung Han
    Choe, Jun-Ho
    Shin, Jung Hee
    Hahn, Soo Yeon
    Oh, Young Lyun
    Chung, Jae Loon
    [J]. ENDOCRINE-RELATED CANCER, 2017, 24 (02) : 97 - 106
  • [4] [Anonymous], J PATHOL
  • [5] Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer
    Bastman, Jill J.
    Serracino, Hilary S.
    Zhu, Yuwen
    Koenig, Michelle R.
    Mateescu, Valerica
    Sams, Sharon B.
    Davies, Kurtis D.
    Raeburn, Christopher D.
    McIntyre, Robert C., Jr.
    Haugen, Bryan R.
    French, Jena D.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (07) : 2863 - 2873
  • [6] AKT1E17K in human solid tumours
    Bleeker, F. E.
    Felicioni, L.
    Buttitta, F.
    Lamba, S.
    Cardone, L.
    Rodolfo, M.
    Scarpa, A.
    Leenstra, S.
    Frattini, M.
    Barbareschi, M.
    Del Grammastro, M.
    Sciarrotta, M. G.
    Zanon, C.
    Marchetti, A.
    Bardelli, A.
    [J]. ONCOGENE, 2008, 27 (42) : 5648 - 5650
  • [7] Vemurafenib: the first drug approved for BRAF-mutant cancer
    Bollag, Gideon
    Tsai, James
    Zhang, Jiazhong
    Zhang, Chao
    Ibrahim, Prabha
    Nolop, Keith
    Hirth, Peter
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (11) : 873 - 886
  • [8] Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases
    Bonhomme, Benjamin
    Godbert, Yann
    Perot, Gaelle
    Al Ghuzlan, Abir
    Bardet, Stephane
    Belleannee, Genevieve
    Criniere, Lise
    Do Cao, Christine
    Fouilloux, Genevieve
    Guyetant, Serge
    Kelly, Antony
    Leboulleux, Sophie
    Buffet, Camille
    Leteurtre, Emmanuelle
    Michels, Jean-Jacques
    Tissier, Frederique
    Toubert, Marie-Elisabeth
    Wassef, Michel
    Pinard, Clemence
    Hostein, Isabelle
    Soubeyran, Isabelle
    [J]. THYROID, 2017, 27 (05) : 682 - 692
  • [9] A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis
    Bui, Nam Q.
    Przybyl, Joanna
    Trabucco, Sally E.
    Frampton, Garrett
    Hastie, Trevor
    van de Rijn, Matt
    Ganjoo, Kristen N.
    [J]. CLINICAL SARCOMA RESEARCH, 2019, 9 (01)
  • [10] Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer
    Cantara, Silvia
    Bertelli, Eugenio
    Occhini, Rossella
    Regoli, Mari
    Brilli, Lucia
    Pacini, Furio
    Castagna, Maria Grazia
    Toti, Paolo
    [J]. ENDOCRINE, 2019, 64 (01) : 122 - 129